HYBRID EVENT: You can participate in person at Valencia, Spain or Virtually from your home or work.
Drug Screening
Drug Screening (DS) is used in the ER for pre-employment testing and identifies the most commonly abused substances, such as cocaine, opiates, tranquillizers, sedatives-barbiturates, and hallucinogens. It is a method for determining the presence of one or more drugs of abuse, usually in urine, by "stat" methods, such as EMIT (enzyme-mediated immunologic technique), FPIA (fluorescence polarisation immunoassay). The first step in the procedure is to identify a condition or a therapeutic field with an unmet need. A "druggable" target is identified, and drug screening then begins. Molecules that can interact with the target and/or support the intended phenotypic response are found during drug screening.
Committee Members
Yong Xiao Wang
Albany Medical College, United States
Consolato M Sergi
Universities of Alberta and Ottawa, Canada
Vladlen Slepak
University of Miami Miller School of Medicine, United States
Andreas M Papas
Antares Health Products, United States PDDS 2025 Speakers
Axel H Schonthal
University of Southern California, United States
Bernd Blobel
University of Regensburg, Germany
Srividya Narayanan
Northeastern University, United States
Daisy Mills
University College London, United Kingdom
Maria Richards Brown
University College London, United Kingdom
Gurpreet Singh
IQVIA, United KingdomSubmit your abstract Today
Title : Medical liver biopsy: Toward a personalized approach
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Emerging formulation and delivery applications of vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Mathematical modeling the disc diffusion test: Antibacterial activity of copper-doped SnO2
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Antibody-proteases as translational tools of the next-step generation to be applied for biopharmacy-related and precision medical practice
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Storage stability and solution binding affinity of an fc-fusion mimetic
Hanieh Khalili, University of East London, United Kingdom
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia